Nutriband Acquires 4P Therapeutics; Creates Transdermal & Topical Arm

Nutriband Inc. recently announced the acquisition of 4P Therapeutics Inc. on April 5, 2018. Nutriband has acquired 100% interest in 4P Therapeutics for a total of $1,900,000 payable in both company stock and cash. 4P Therapeutics will receive 250,000 shares of common stock and a cash amount of $400,000. Steven Damon, CEO of 4P Therapeutics, has been appointed to the Nutriband Inc. Board of Directors.

4P Therapeutics will now become the Pharmaceutical and Development arm of Nutriband Inc. with a specific focus on Transdermal and Topical Technologies, prescription drugs, and clinical development.

Included in the acquisition of 4P’s IP Portfolio is Defent abuse-deterrent patch technology, an opioid abuse-deterrent platform for the transdermal delivery of opioid-based medications. Defent lowers the risk of abuse and misuse, creating a safer treatment for patients.

Nutriband has also acquired 4P’s Exenatide transdermal delivery system, currently in Phase I clinical development. If successfully taken through Phase III and to commercialization, it will compete with injectable Exenatide, such as Byetta and Bydureon, by providing an injection-free alternative for patients with type II diabetes. A full pipeline of drugs and technology can be found on 4P’s website http://www.4ptherapeutics.com/.

4P Therapeutics is a private company focused on the research and development of novel drug delivery technologies and therapeutics. 4P develops products that meet the needs of patients, physicians, and payers. The company has capabilities for developing pharmaceutical products ranging from preclinical testing to clinical manufacturing and early stage clinical development (Phase I/II). A key company focus and area of expertise is in the development of transdermal products for currently injected compounds, including proteins, peptides, macromolecules, and biologics. Transdermal delivery of commercially available drugs or biologics that are typically delivered via injection has the potential to improve safety, efficacy, and therapeutic outcomes associated with these treatments.

Nutriband Inc. appointed Steven Damon to its Board of Directors. Steven Damon has over 30 years of experience with various business roles in the medical and pharmaceutical industries. As well as founding 4P Therapeutics, Steven also maintains an executive leadership role as Vice President for Business and Commercial Development with Femasys an Atlanta based women’s healthcare medtech company. In addition, he serves on the boards of Micron Biomedical, Carmel Bioscience, Temple Therapeutics, and Georgia BIO. He actively consults with various companies on strategy, financing, and M&A.

Before founding 4P Therapeutics, Steven led the Business Development team at Atlanta-based Altea Therapeutics as the company’s Senior Vice President of Business Development. He founded and was President of Absorbable Polymers International a Birmingham, AL, company. He was an Executive Director at DURECT Corporation in Cupertino CA, where he led Business Development activities and was responsible for the ALZET research drug delivery pump business. He started his life science career with Kimberly-Clark Healthcare (now Halyard Healthcare) with lead responsibilities for commercial development of the healthcare business in Europe and the acquisitions of a number of life science companies and products. Additional activities include industry related speaking engagements, publications and committee participation.

Nutriband Inc. appointed Alan Smith, PhD, as Head of Regulatory and Clinical Operations. He co-founded 4P Therapeutics in 2011 and serves as Vice President, Clinical, Regulatory, Quality, and Operations. Previously, he was with Altea Therapeutics, most recently serving as Vice President, Product Development and Head of Clinical R&D, Regulatory Affairs, and Project Management. At Altea, he led major research and development programs with pharmaceutical companies such as Eli Lilly, Amylin, Hospira, Elan, and Novartis.

Nutriband is a unique, result’s driven, health and pharmaceutical company based in Orlando FL. Unlike traditional health product companies, Nutriband found its start by spotting and targeting a gross and virtually unexplored niche in the market through its method of ingredient delivery. All Nutriband products are based around the science of transdermal/topical technologies. For more information, visit http://www.nutriband.com/.